These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 25036701)

  • 1. A brain network response to sham surgery.
    Cherkasova MV; Stoessl AJ
    J Clin Invest; 2014 Aug; 124(8):3285-8. PubMed ID: 25036701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Network modulation following sham surgery in Parkinson's disease.
    Ko JH; Feigin A; Mattis PJ; Tang CC; Ma Y; Dhawan V; During MJ; Kaplitt MG; Eidelberg D
    J Clin Invest; 2014 Aug; 124(8):3656-66. PubMed ID: 25036712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence-Based Evaluation of the Ethics of Sham Surgery for Parkinson's Disease.
    Polgar S; Mohamed S
    J Parkinsons Dis; 2019; 9(3):565-574. PubMed ID: 31282423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Placebo response in Parkinson's disease: comparisons among 11 trials covering medical and surgical interventions.
    Goetz CG; Wuu J; McDermott MP; Adler CH; Fahn S; Freed CR; Hauser RA; Olanow WC; Shoulson I; Tandon PK; ; Leurgans S
    Mov Disord; 2008 Apr; 23(5):690-9. PubMed ID: 18228568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurobiology of placebo effect in Parkinson's disease: What we have learned and where we are going.
    Quattrone A; Barbagallo G; Cerasa A; Stoessl AJ
    Mov Disord; 2018 Aug; 33(8):1213-1227. PubMed ID: 30230624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What is the risk of sham surgery in Parkinson disease clinical trials? A review of published reports.
    Frank S; Kieburtz K; Holloway R; Kim SY
    Neurology; 2005 Oct; 65(7):1101-3. PubMed ID: 16033990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of metabolic brain networks after subthalamic gene therapy for Parkinson's disease.
    Feigin A; Kaplitt MG; Tang C; Lin T; Mattis P; Dhawan V; During MJ; Eidelberg D
    Proc Natl Acad Sci U S A; 2007 Dec; 104(49):19559-64. PubMed ID: 18042721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Science and ethics of sham surgery: a survey of Parkinson disease clinical researchers.
    Kim SY; Frank S; Holloway R; Zimmerman C; Wilson R; Kieburtz K
    Arch Neurol; 2005 Sep; 62(9):1357-60. PubMed ID: 16157742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Placebo responses in Parkinson's disease.
    Lou JS
    Int Rev Neurobiol; 2020; 153():187-211. PubMed ID: 32563288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of Abnormal Metabolic Brain Networks by Experimental Therapies in a Nonhuman Primate Model of Parkinson Disease: An Application to Human Retinal Pigment Epithelial Cell Implantation.
    Peng S; Ma Y; Flores J; Cornfeldt M; Mitrovic B; Eidelberg D; Doudet DJ
    J Nucl Med; 2016 Oct; 57(10):1591-1598. PubMed ID: 27056614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of the thalamic-subthalamic circuit involved in the placebo response through single-neuron recording in Parkinson patients.
    Frisaldi E; Carlino E; Lanotte M; Lopiano L; Benedetti F
    Cortex; 2014 Nov; 60():3-9. PubMed ID: 24457096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Placebos that harm: sham surgery controls in clinical trials.
    London AJ; Kadane JB
    Stat Methods Med Res; 2002 Oct; 11(5):413-27. PubMed ID: 12357587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What influences placebo and nocebo responses in Parkinson's disease?
    Witek N; Stebbins GT; Goetz CG
    Mov Disord; 2018 Aug; 33(8):1204-1212. PubMed ID: 30132980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Great expectations: the placebo effect in Parkinson's disease.
    Lidstone SC
    Handb Exp Pharmacol; 2014; 225():139-47. PubMed ID: 25304530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene therapy reduces Parkinson's disease symptoms by reorganizing functional brain connectivity.
    Niethammer M; Tang CC; Vo A; Nguyen N; Spetsieris P; Dhawan V; Ma Y; Small M; Feigin A; During MJ; Kaplitt MG; Eidelberg D
    Sci Transl Med; 2018 Nov; 10(469):. PubMed ID: 30487248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing the risk of a necessary harm: placebo surgery in Parkinson disease.
    Rascol O
    Neurology; 2005 Oct; 65(7):982-3. PubMed ID: 16217047
    [No Abstract]   [Full Text] [Related]  

  • 17. Teaching neurons to respond to placebos.
    Benedetti F; Frisaldi E; Carlino E; Giudetti L; Pampallona A; Zibetti M; Lanotte M; Lopiano L
    J Physiol; 2016 Oct; 594(19):5647-60. PubMed ID: 26861164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abnormal metabolic brain network associated with Parkinson's disease: replication on a new European sample.
    Tomše P; Jensterle L; Grmek M; Zaletel K; Pirtošek Z; Dhawan V; Peng S; Eidelberg D; Ma Y; Trošt M
    Neuroradiology; 2017 May; 59(5):507-515. PubMed ID: 28386687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is exenatide the next big thing in Parkinson's disease?
    Simuni T; Brundin P
    J Parkinsons Dis; 2014; 4(3):345-7. PubMed ID: 24748153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sham surgery controls in Parkinson's disease clinical trials: views of participants.
    Kim SY; De Vries R; Holloway RG; Wilson R; Parnami S; Kim HM; Frank S; Kieburtz K
    Mov Disord; 2012 Sep; 27(11):1461-5. PubMed ID: 22927064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.